TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and above~* First diagnosis of C. difficile infection~* Treatment for C. difficile infection less than 24 hours~* Female subjects must be nonpregnant, nonlactating, and either postmenopausal for at least 1 year, surgically sterile (i.e., documented tubal ligation or hysterectomy) for at least 90 days, abstinent, or agree to use 1 of the following forms of contraception from the time of signing the Informed Consent form (ICF) until 30 days after leaving the study site: a nonhormonal intrauterine device (IUD) with spermicide, female condom with spermicide, contraceptive sponge with spermicide, diaphragm with spermicide, cervical cap with spermicide, a male sexual partner who agrees to use a male condom with spermicide, or a sterile sexual partner.~Exclusion Criteria:~* History of hypersensitivity to fidaxomicin or vancomycin~* Pregnant or breast-feeding~* Active treatment with other therapies with activity against C. difficile~* Receiving any peristaltic agents~* Medical history including ulcerative colitis or Chron's disease~* Ordered to be nothing by mouth or cannot swallow the study medication~* Participation in another clinical research study utilizing pharmacological treatment within 1 month or five half-lives of the medication whichever is longer~* Any other reason felt by the investigator to potentially affect the outcomes of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fidaxomicin (Type: ACTIVE_COMPARATOR): Fidaxomicin 200mg by mouth every 12 hours for 10 days
- Vancomycin (Type: ACTIVE_COMPARATOR): Vancomycin 125mg by mouth every 6 hours for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older, of either gender, and of any race~* Naïve to moderately or highly emetogenic chemotherapy, and is to receive a first course of MEC including one or more of the following agents: cyclophosphamide IV (\<1500 mg/m2), doxorubicin, epirubicin, carboplatin, idarubicin, ifosfamide, irinotecan, daunorubicin, cytarabine IV (\>1 g/m2).~* Karnofsky performance score of ≥60~* Predicted life expectancy of ≥4 months~* Adequate bone marrow, kidney, and liver function~Exclusion Criteria:~* Contraindication to the administration of prescribed MEC agent,granisetron, or dexamethasone~* Is pregnant or breast feeding~* Has taken the following agents within the last 48 hours 5-HT3 antagonists,Phenothiazines,Benzamides,Domperidone,Cannabinoids,NK1 antagonist, Benzodiazepines~* Scheduled to receive any other chemotherapeutic agent with an emetogenicity level of 3 or above (Hesketh Scale) from Day -2 through Day 6, except on Day 1~* Scheduled to receive any radiation therapy to the abdomen or pelvis from Day -5 through Day 6~* Has received systemic corticosteroids or sedative antihistamines within 72 hours of Day 1 of the study except as premedication for chemotherapy (e.g., taxanes)~* Symptomatic primary or metastatic CNS disease.~* Has ongoing vomiting, retching, clinically significant nausea caused by any etiology, or has a history of anticipatory nausea and vomiting.~* Has vomited and/or has had dry heaves/retching within 24 hours prior to the start of MECon Day 1 in Cycle 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo + Granisetron + Dexamethasone (Type: PLACEBO_COMPARATOR): Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
- Rolapitant (Type: EXPERIMENTAL): Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cheese Consumption and Human Microvascular Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Seated systolic pressure 120-140 mmHg~* Seated diastolic pressure 70-90 mmHg.~* Normoglycemic (HbA1C \<5.7%)~Exclusion Criteria:~* Taking pharmacotherapy that alters peripheral vascular control~* Pregnancy~* Breastfeeding~* Females taking contraceptives (pills, patches, shots, etc.) or hormone replacement therapy~* Taking illicit and/or recreational drugs~* Use of nicotine containing-products (e.g. smoking, chewing tobacco, etc.)~* Known allergy to latex or investigative substances

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Baseline (Type: ACTIVE_COMPARATOR): Subjects on normal personal diet Acetylcholine (ACh) Dose Response, Local heating (LH), and Flow Mediated Dilation with nitroglycerin experiments
- Low Sodium, No Cheese (Type: EXPERIMENTAL): Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments
- Low Sodium, Cheese (Type: EXPERIMENTAL): Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments
- High Sodium, No Cheese (Type: EXPERIMENTAL): Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments
- High Sodium, Cheese (Type: EXPERIMENTAL): Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~All Participants~* For a female of childbearing potential: either be sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or be using an acceptable birth control method. Females of non-childbearing potential must have undergone a sterilization procedure at least 6 months prior to the first dose~* Non-vasectomized male participants must agree to use a condom with spermicide or abstain from sexual intercourse during the trial and for 90 days after stopping the study medication and agree not to donate sperm during this time period Participants with ESRD on HD~* Maintained on a stable regimen of HD within 3 months prior to first dosing Participants with Severe Renal Impairment~* Estimated glomerular filtration rate (eGFR) at screening is \< 30 mL/min/1.73m\^2 Healthy Controls~* Participant is within ± 10 years of the mean age and within 10% of the mean body mass index of severe renal impairment participants~* eGFR at screening is \>=80 mL/min/1.73m\^2~Exclusion Criteria:~All Participants~* History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, or neurological disease whose current condition is considered unstable~* History or presence of alcoholism and drug abuse within the past 6 months~* Female participants who are pregnant or lactating~* Regular user of any medication (including over the counter) that would significantly alter GFR~* Donation of blood or significant blood loss within 56 days prior to the first dose of study medication(s)~* Plasma donation within 7 days prior to the first dose of study medication(s)~* A renal transplant or nephrectomy Participants with ESRD or Severe Renal Impairment~* Rapidly fluctuating renal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Participants with End Stage Renal Disease on Hemodialysis (Type: EXPERIMENTAL): Participants with End Stage Renal Disease on hemodialysis received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days..
- Participants with Severe Renal Impairment (Type: EXPERIMENTAL): Participants with Severe Renal Impairment (estimated glomerular filtration rate \<30 mL/min/1.73 m\^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
- Healthy Participants (Type: EXPERIMENTAL): Healthy participants (estimated glomerular filtration rate \>=80 mL/min/1.73 m\^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled within three weeks of the screening visit to undergo elective orthopedic surgery.~* Moderate to severe pain within 6 hours following completion of the required surgery.~Exclusion Criteria:~* Chronic pain conditions.~* Chronic disease or recent cardiovascular events.~* Known allergy or hypersensitivity to the active compounds or any of the excipients used in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): DIC075V (IV diclofenac)
- B (Type: ACTIVE_COMPARATOR): IV Ketorolac
- C (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Must provide written informed consent,~* Be between 12 years of age and older,~* Male or Female, females of non-child bearing potential or using reliable contraception~* Asthma for at least 6 months, FEV1 (forced expiratory volume in 1 second) between 50-80% of predicted value, and reversibility greater than or equal to 15% following 180 mcg albuterol~* Stable low dose of Inhaled Corticosteroids~* Non-smoker, 12 months smoking-free and \<=10-pack years history~* Otherwise healthy~* Other criteria apply~Exclusion Criteria:~* Pregnant~* Allergic to albuterol or severe milk protein allergy~* Must not be on another trial for 30days.~* Other criteria apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albuterol Spiromax® 90 mcg (Type: EXPERIMENTAL): A single dose of albuterol 90 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.
- Albuterol Spiromax® 180 mcg (Type: EXPERIMENTAL): A single dose of albuterol 180 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
- ProAir® HFA 90 mcg (Type: ACTIVE_COMPARATOR): A single dose of albuterol 90 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
- ProAir® HFA 180 mcg (Type: ACTIVE_COMPARATOR): A single dose of albuterol 180 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
- Placebo Inhaler (Type: PLACEBO_COMPARATOR): Placebo delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xenogeneic Collagen Matrix as an Alternative to Free Gingival Grafting for Oral Soft Tissue Augmentation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least two non-adjacent teeth in contralateral quadrants of the same jaw with \< 2mm of KT that requires soft tissue grafting (1-4 teeth may be treated). In case of adjacent teeth requiring grafting, only one tooth at each site will act as test or control tooth, but all teeth will get the same treatment). The number of teeth treated must be the same on the test and control sites.~  * Root coverage is not desired at the time of grafting.~ * Females of childbearing potential must have a documented negative urine pregnancy test.~ * Read, understood and signed an institutional review board (IRB) approved Informed Consent Form (ICF).~ * Able and willing to follow study procedures and instructions.~ * Multi-rooted teeth may be treated but will not be included as study teeth~Exclusion Criteria:~* Vestibule depth of less than 7mm from base of recession, and/or teeth with Miller Grade 2 or higher mobility.~  * Any systemic conditions (i.e., diabetes mellitus, cancer, HIV, bone metabolic diseases) that could compromise wound healing and/ or preclude periodontal surgery; or who are currently receiving or have received within two months prior to study entry, systemic corticosteroids, immunosuppressive agents, radiation therapy, and/or chemotherapy which could compromise wound healing and preclude periodontal surgery.~ * Presence of acute infectious lesions in the areas intended for surgery.~ * History of any tobacco use within the last six months.~ * Taking intramuscular or intravenous bisphosphonates.~ * Known hypersensitivity to collagen products, and/or allergy to iodine or shellfish.~ * Participating in other clinical studies involving therapeutic intervention (either medical or dental).~ * Previously undergone a gingival grafting procedure on the test or control teeth or the teeth adjacent to the study site.~ * Female subjects who are pregnant or lactating, or who intend to become pregnant during the study duration following entrance into the study.~ * Subjects, who in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- xenogeneic collagen matrix (Type: ACTIVE_COMPARATOR): Xenogeneic collagen matrix device placed on treatment wound bed site
- Free Gingival Graft (Type: ACTIVE_COMPARATOR): Traditional free gingival graft (autogenous graft device harvested from patient's palate) placed on treatment site wound bed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects with T1DM for at least 1 year; diagnostic criteria as defined by the American Diabetes Association (3).~* Treated with insulin for T1DM for at least 1 year and with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening~* Hemoglobin A1c \<10%.~* Aged between 18 and 75 years, both inclusive.~Exclusion Criteria:~* Previous participation in a clinical trial within the dasiglucagon in the rescue treatment of hypoglycemia program.~* Known or suspected allergy to trial drug(s) or related products.~* History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).~* Previous participation in this trial. Participation being defined by signing the informed consent document.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dasiglucagon (Type: EXPERIMENTAL): single fixed dose (subcutaneous injection) of dasiglucagon
- Placebo (Type: PLACEBO_COMPARATOR): single fixed dose (subcutaneous injection) of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine in Children for Magnetic Resonance Imaging (MRI) Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MRI~* ASA I-II~Exclusion Criteria:~* hepatic and renal failure~* difficult airway~* nasal deformity~* anaphylaxis to dexmedetomidine~* neurologic disease~* metabolic disorders~* electrolyte imbalance~* dehydration~* malnutrition

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine 3mcg/kg (Type: ACTIVE_COMPARATOR): dexmedetomidine 3 mcg/kg intranasal 50 minutes before MRI
- dexmedetomidine 4mcg/kg (Type: ACTIVE_COMPARATOR): dexmedetomidine 4 mcg/kg intranasal 50 minutes before MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Sulphate Injection in Treatment of Myofascial Trigger Points

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Definite diagnosis of myofascial pain with a referral, based on the DC/TMD criteria~* the presence of one or more trigger points in the unilateral or bilateral masseter muscle~* no history of any invasive procedures in the related masseter muscle.~Exclusion Criteria:~* Factors that can cause pain in the orofacial region other than MTPs (decayed tooth, TMJ internal disorder).~* Any systemic disease that possibly affects the masticatory system such as rheumatoid arthritis and epilepsy~* pregnancy and lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- group I (Type: ACTIVE_COMPARATOR): each patient injected 0.5ml in each TrPs of saline by the same operator
- group II (Type: EXPERIMENTAL): each patient injected 0.5ml in each TrPs of magnesium sulphate by the same operator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
1. Inclusion Criteria:~   a. Patients who are 18 years of age and older, and who agreed to participate in the study will be included in the study.~2. Exclusion Criteria:~   1. Patients having received analgesic in the last six hours,~  2. pregnant women,~  3. women of childbearing potential and not using birth control,~  4. those who do not agree to participate in the study,~  5. those under age of 18, those who have signs of peritoneal irritation,~  6. those who are allergic to drugs used in the study,~  7. hemodynamically unstable patients,~  8. patients with renal transplant,~  9. those who suffer from liver, kidney, cardiac and pulmonary insufficiency and others with systemic diseases,~  10. patients with vision problems and those who are illiterate will be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paracetamol (Type: EXPERIMENTAL): Paracetamol which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
- Dexketoprofen (Type: ACTIVE_COMPARATOR): Dexketoprofen which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete